Future share price movements for Rocket Pharmaceuticals depend heavily on upcoming clinical trial data readouts, regulatory milestones with agencies like the FDA, and capital management. While Wall Street analysts maintain an average 12-month consensus price target hovering near $8.84 to $9.60, clinical-stage biotechnology equities carry high inherent volatility.